Integrated analysis identifies an immune-based prognostic signature for the mesenchymal identity in colorectal cancer
Open Access
- 19 June 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (25) , e20617
Abstract
Background: Colorectal cancer (CRC) has been divided into 4 consensus molecular subtypes (CMSs), of which CMS4 has the mesenchymal identity and the highest relapse rate. Our goal is to develop a prognostic signature by integrating the immune system and mesenchymal modalities involved in CMS4. Methods: The gene expression profiles collected from 5 public datasets were applied to this study, including 1280 samples totally. Network analysis was applied to integrate the mesenchymal modalities and immune signature to establish an immune-based prognostic signature for CRC (IPSCRC). Results: We identified 6 immune genes as key factors of CMS4 and established the IPSCRC. The IPSCRC could significantly divide patients into high- and low- risk groups in terms of relapse-free survival (RFS) and overall survival (OS) and in discovery (RFS:P < .0001) and 4 independent validation sets (RFS range:P = .01 to P = .02-.0004). After stage stratification, the IPSCRC could still distinguish poor prognosis patients in discovery (RFS:P = .04) and validation cohorts (RFS range:P = .04-.007) within stage II in terms of RFS. Further, in multivariate analysis, the IPSCRC remained an independent predictor of prognosis. Moreover, Macrophage M2 was significantly enriched in the high-risk group, while plasma cells enriched in the low-risk group. Conclusion: We propose an immune-based signature identified by network analysis, which is a promising prognostic biomarker and help for the selection of CRC patients who might benefit from more rigorous therapies. Further prospective studies are warranted to test and validate its efficiency for clinical application.Keywords
Funding Information
- Zhejiang Province Public Welfare Technology Application Research Project (LGF19H200001)
This publication has 41 references indexed in Scilit:
- Modeling the prevention of colorectal cancer from the combined impact of host and behavioral risk factorsGenetics in Medicine, 2017
- Screening for Colorectal NeoplasiaNew England Journal of Medicine, 2017
- Global patterns and trends in colorectal cancer incidence and mortalityGut, 2016
- Global burden of cancer attributable to high body-mass index in 2012: a population-based studyThe Lancet Oncology, 2015
- Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus OxaliplatinJournal of Clinical Oncology, 2013
- Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinomaGut, 2013
- Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal CancerJournal of Clinical Oncology, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Stage II Colon Cancer Prognosis Prediction by Tumor Gene Expression ProfilingJournal of Clinical Oncology, 2006
- Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon CancerJournal of Clinical Oncology, 2004